PillRx only · Spray, Metered · Nasal
Olopatadine Hydrochloride And Mometasone Furoate
Brands: Ryaltris · Mometasone Furoate Monohydrate + Olopatadine Hydrochloride
2 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US2 NDCs
2 active makers
2 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
ATC—
RxCUI (US)—
US makers2 labelers
Packages4
DEA / ScheduleNone
US acquisition costNADAC · per unit
Average across 2 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$7.671
Latest avg · Jul 22, 2026
-7%
Since Dec 17, 2025
2
Active US suppliers
100%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
1.7K
Rx · 2026 Q1
51K
Units dispensed
-39%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it2 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Glenmark Pharmaceuticals Inc., USA | unknown | 2 | SUPPLYING |
| Hikma Specialty USA Inc. | unknown | 2 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Sep 24, 2024RECALLRecall (Class II): Ryaltris (olopatadine hydrochloride and mometasone fluorate) Nasal Spray, 665 mcg/25 mcg per spray, 240 Metered Sprays/…
Defective Delivery System: The dip tube is clogged causing the spray not to work. — Recalling firm: Glenmark Pharmaceuticals Inc., USA — Nationwide in the USA